haematology
Blood cancers

Venetoclax gets PBS listing for CLL

Clinicians from the research institute that helped discover venetoclax (Venclexta) have welcomed its listing on the PBS for people with relapsed or refractory chronic lymphocytic leukaemia (CLL). From 1 March 2019, venetoclax will be subsidised in combination with rituximab for the treatment of certain patients with relapsed or refractory chronic lymphocytic leukaemia who have received ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic